Dacomitinib Bests Erlotinib in Advanced Non-Small Cell Lung Cancer

Jill Stein
Published: Tuesday, Oct 23, 2012
Dr. Suresh S. Ramalingam

Suresh S. Ramalingam, MD

Investigators are reporting improved progression-free survival (PFS) after treatment with the investigational agent dacomitinib compared with erlotinib in patients with non–small cell lung cancer (NSCLC) experiencing progression during chemotherapy.

Table. Median PFS Across Subgroups in Phase II Trial of Dacomitinib Versus Erlotinib in Advanced NSCLC

  Dacomitinib Erlotinib Hazard Ratio
Overall 2.86 mo 1.91 mo 0.66
KRAS wild-type 3.71 mo 1.91 mo 0.55
KRAS wild-type/
EGFR wild-type
2.21 mo 1.84 mo 0.61
EGFR-mutant 7.44 mo 7.44 mo 0.46

mo indicates months; NSCLC, non–small cell lung cancer; PFS, progression-free survival.

An improvement in PFS was noted in most clinical and molecular subgroups (Table). In patients with KRAS wild-type tumors, the median PFS was 3.71 months and 1.91 months for the dacomitinib and erlotinib treatment arms, respectively (HR = 0.55; 95% CI, 0.35-0.85; two-sided P = .006). Patients with KRAS wild-type/EGFR wild-type tumors receiving dacomitinib had a median PFS of 2.21 months compared with 1.84 months for patients treated with erlotinib (HR = 0.61; 95% CI, 0.37-0.99; two-sided P = .043).

Ramalingam SS, Blackhall F, Krzakowski M, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small- cell lung cancer. J Clin Oncol. 2012;30(27):3337-3344.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Oncology Nursing News
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Articles
Blogs
Conference Coverage
OncLive TV
Peer Exchange
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Forgot Password
Press Releases
Privacy Policy
Terms & Conditions
 
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.
 
x